Photoacoustic Imaging to Study Lymph Node Changes in Head and Neck Cancer
Uses photoacoustic imaging to track lymph nodes in head and neck cancer during treatment.
Key facts
- Who runs it
- Sunnybrook Health Sciences Centre
- Where
- Toronto, CanadaSee the site
- Trial code
- Registry title
- Pilot Study to Evaluate Photoacoustic Imaging in Head and Neck Cancer
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 23 Apr 2019
- Expected to end
- 23 Apr 2027
- Type of study
- Observational
- Treatments tested
- Photoacoustic Imaging System
- Record updated
- 13 December 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with head and neck cancer that has not been treated yet and will be treated with radiotherapy. Photoacoustic imaging is used to look at lymph nodes during treatment.
- Sex
- All sexes can join.
- Disease stage
- Head and neck cancer confirmed under the microscope, not yet treated with any first-line therapy, with disease that can be measured by ultrasound or MRI within 28 days before treatment.
- Earlier treatment
- No first-line therapy before. No chemotherapy, radiotherapy or major surgery within 4 weeks before joining.
Main reasons for not taking part
- Receiving any other investigational agents
- Known brain metastases
- Previous radiotherapy to an involved area
- Serious infection needing antibiotic, antifungal or antiviral treatment
- Symptomatic heart failure, unstable angina or heart rhythm problems
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Histologically or cytologically confirmed head and neck carcinoma which has not been treated with any first-line therapy and will be treated with radiotherapy
- Measurable disease by ultrasound, or MRI performed within 28 days prior to treatment
- Eastern Co-operative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy of at least 6 months
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to dosing:; hemoglobin >90 mg/dL; leukocytes >3,000/mL; absolute neutrophil count >1,500/mL; platelets >100,000/mL; total bilirubin within normal institutional limits; AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional upper limit of normal
- Subjects must give appropriate written informed consent prior to participation in the study
- Subjects must be able and willing to comply with the safety procedures during the Scanning Period
Who cannot take part
- Chemotherapy, radiotherapy, or major surgery within 4 weeks prior to registering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registration
- Receiving any other investigational agents
- Contraindications to radiotherapy such as but not limited to:; previous radiotherapy to an involved area; active collagen vascular disease; genetic diseases associated with hyper-radiosensitivity
- History of allergic reactions attributed to compounds of similar chemical or biologic composition
- Any clinically serious infections requiring systemic anti-bacterial, antifungal or antiviral therapy
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection,
- Symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia
- History of active ongoing seizure disorder
- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- Known brain metastases
Where in Canada
- Sunnybrook Health Sciences CentreToronto, CanadaContact: Gregory J Czarnota, PhD, MDTaking people
About the trial
What the trial wants to find out
In this study, PA imaging will be used to examine the physiological and physical changes in lymph node involvements of head and neck cancer during radiotherapy with or without chemotherapy. Our objective in this pilot study will be to evaluate if PA parameters change within the lymph node involvements during chemoradiation therapy over time. Our hope is to use this information to correlate the changes in measured PA parameters with radiological response.
The group in the trial
- Radiotherapy Response Monitoring
Those undergoing radiation therapy treatment to their lymph nodes upon diagnosis of head and neck cancer
Treatment: Photoacoustic Imaging System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pilot Study to Evaluate Photoacoustic Imaging in Head and Neck Cancer
- Plain-language title
- Photoacoustic Imaging to Study Lymph Node Changes in Head and Neck CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 December 2023